Humana Inc. (NYSE:HUM) had its price target raised by Bank of America Corporation from $270.00 to $275.00 in a research note released on Friday. They currently have a buy rating on the insurance provider’s stock.
A number of other brokerages have also recently commented on HUM. Zacks Investment Research cut shares of Humana from a buy rating to a hold rating in a research report on Monday, April 24th. Cowen and Company reiterated an outperform rating and set a $230.00 price target on shares of Humana in a research report on Tuesday, April 25th. Credit Suisse Group reiterated an outperform rating and set a $250.00 price target (up from $245.00) on shares of Humana in a research report on Thursday, July 13th. Cantor Fitzgerald reiterated a neutral rating on shares of Humana in a research report on Friday, June 23rd. Finally, UBS Group AG reiterated a neutral rating and set a $237.00 price target (up from $205.00) on shares of Humana in a research report on Wednesday, June 28th. Nine research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $231.00.
Shares of Humana (NYSE HUM) traded down 1.05% during midday trading on Friday, hitting $235.06. 1,575,295 shares of the company traded hands. The stock has a 50 day moving average of $232.54 and a 200-day moving average of $215.15. Humana has a 52 week low of $150.00 and a 52 week high of $243.74. The stock has a market capitalization of $33.92 billion, a PE ratio of 23.96 and a beta of 0.91.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.20. The company had revenue of $13.76 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 2.71% and a return on equity of 14.38%. During the same period in the prior year, the business earned $1.86 earnings per share. Equities analysts forecast that Humana will post $11.15 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2017/07/18/bank-of-america-corporation-boosts-humana-inc-hum-price-target-to-275-00.html.
The company also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Shareholders of record on Friday, June 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.68%. Humana’s dividend payout ratio is currently 16.24%.
In related news, VP Timothy S. Huval sold 13,939 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $225.86, for a total value of $3,148,262.54. Following the transaction, the vice president now directly owns 23,639 shares of the company’s stock, valued at approximately $5,339,104.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jody L. Bilney sold 4,600 shares of the business’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $230.16, for a total value of $1,058,736.00. Following the completion of the transaction, the senior vice president now directly owns 8,978 shares in the company, valued at $2,066,376.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 143,241 shares of company stock valued at $32,446,903. Corporate insiders own 0.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock valued at $2,553,487,000 after buying an additional 11,867,056 shares during the period. FMR LLC boosted its stake in shares of Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock valued at $1,041,184,000 after buying an additional 1,851,197 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock valued at $554,867,000 after buying an additional 1,231,400 shares during the period. Wellington Management Group LLP boosted its stake in shares of Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock valued at $159,915,000 after buying an additional 747,557 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock valued at $151,723,000 after buying an additional 592,772 shares during the period. 99.04% of the stock is currently owned by institutional investors.
About Humana
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
